


PRODUCT: Rebastinib (DCC-2036)

ALTERNATE NAMES: DCC-2036; DCC-2036; DCC2036; Bcr-Abl inhibitor; Bcr-abl inhibitor; 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoyl amino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide

CATALOG #: B1619-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₃₀H₂₈FN₇O₃

MOLECULAR WEIGHT: 553.59

CAS NUMBER: 1020172-07-9

APPEARANCE: White solid powder

SOLUBILITY: DMSO

PURITY: >98%

STORAGE: Store at -20°C. Protect from air and light

DESCRIPTION: DCC-2036 (Rebastinib) is an inhibitor of Bcr-Abl with IC₅₀ of 0.8 nM and 4 nM for Abl1(WT) and Abl1(T315I), respectively.

REFERENCES: 1. Chan W W, Wise S C, Kaufman M D, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer cell, 2011, 19(4): 556-568.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

- Dasatinib (BMS-354825, Sprycel) (Cat# 1586)
- EZSolution™ Dasatinib (Cat# 2029)
- GZD824 (Cat# 2795)
- GNF-2 (Cat# 2470)
- Imatinib Mesylate (CGP-57148B, STI-571) (Cat# 1625)
- Imatinib, Free base (Cat# 2141)
- Nilotinib (Cat# 1750)
- Ponatinib (Cat# 2712)
- Radotinib (Cat# 9613)
- Saracatinib (AZD0530) (Cat# 1582)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**